Difference between revisions of "Clomipramine-fluvoxamine"
From Psychiatrienet
| Line 11: | Line 11: | ||
| info = | | info = | ||
* Occurrence of serotonin syndrome is theoretically possible, so caution is necessary. | * Occurrence of serotonin syndrome is theoretically possible, so caution is necessary. | ||
| − | * Fluvoxamine is an inhibitor of CYP1A2, CYP2C19 and CYP3A4 (moderate), which metabolize clomipramine.}} | + | * Fluvoxamine is an inhibitor of CYP1A2, CYP2C19 and CYP3A4 (moderate), which metabolize clomipramine. |
| + | {{review}}}} | ||
Revision as of 14:40, 2 November 2015
| ||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
Switch medication from clomipramine to fluvoxamine.[1] [2]
Stop clomipramine - Before day 1: gradually reduce dosage of clomipramine to a maximum of 50 mg/day.
- Day 1: reduce dosage of clomipramine to 25 mg/day.
- Day 8: stop dosage of clomipramine.
Start fluvoxamine- Day 8: start administration of fluvoxamine in a normal dosage of 50 mg/day.
- Day 15: increase dosage of fluvoxamine.
More information- Occurrence of serotonin syndrome is theoretically possible, so caution is necessary.
- Fluvoxamine is an inhibitor of CYP1A2, CYP2C19 and CYP3A4 (moderate), which metabolize clomipramine.
- This switch is currently being reviewed.
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
